SGLT-2 Inhibitors for Non-Alcoholic Fatty Liver Disease: A Review

被引：6
|
作者：
Xu, Rong [1 ,2 ]
Lian, Difei [1 ,2 ]
Xie, Yan [1 ,2 ]
Chen, Zhilei [1 ,2 ]
Wang, Yan [1 ,2 ]
Mu, Lin [1 ,2 ]
Wang, Yuan [1 ,2 ]
Zhang, Baoyu [1 ,2 ]
机构：
[1] Capital Med Univ, Lu He Hosp, Ctr Endocrine Metab & Immune Dis, Beijing 100000, Peoples R China
[2] Beijing Key Lab Diabet Res & Care, Beijing 100000, Peoples R China
来源：
FRONTIERS IN BIOSCIENCE-LANDMARK | 2023年 / 28卷 / 07期
关键词：
SGLT-2; inhibitors; non-alcoholic fatty liver disease; non-alcoholic steatohepatitis; type; 2; diabetes; TYPE-2; DIABETES-MELLITUS; PPAR-ALPHA/GAMMA AGONIST; GLP-1 RECEPTOR AGONISTS; INSULIN-CLEARANCE; DOUBLE-BLIND; INFLAMMASOME ACTIVATION; HEPATIC STEATOSIS; BARIATRIC SURGERY; OBETICHOLIC ACID; REDUCES FEATURES;
D O I：
10.31083/j.fbl2807134
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
Non-alcoholic fatty liver disease (NAFLD) is a group of metabolic liver illnesses that lead to accumulation of liver fat mainly due to excessive nutrition. It is closely related to insulin resistance, obesity, type 2 diabetes, and cardiovascular disease, and has become one of the main causes of chronic liver disease worldwide. At present, there is no specific drug for the treatment of NAFLD; lifestyle interventions including dietary control and exercise are recommended as routine treatments. As a drug for the treatment of type 2 diabetes, sodium-glucose co-transporter type 2 (SGLT-2) inhibitors may also play a beneficial role in the treatment of NAFLD. This article reviews the mechanism of SGLT-2 inhibitors in the treatment of NAFLD.
引用
收藏
页数：12
相关论文
共 50 条
  • [41] Non-alcoholic fatty liver disease: a narrative review of genetics
    Christopher J.Danford
    Zemin Yao
    Z.Gordon Jiang
    The Journal of Biomedical Research, 2018, 32 (06) : 389 - 400
  • [42] Non-alcoholic fatty liver disease: a narrative review of genetics
    Danford, Christopher J.
    Yao, Zemin
    Jiang, Z. Gordon
    JOURNAL OF BIOMEDICAL RESEARCH, 2018, 32 (06): : 389 - 400
  • [43] Review article: fructose in non-alcoholic fatty liver disease
    Yilmaz, Y.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2012, 35 (10) : 1135 - 1144
  • [44] Berberine in Non-Alcoholic Fatty Liver Disease-A Review
    Koperska, Anna
    Wesolek, Agnieszka
    Moszak, Malgorzata
    Szulinska, Monika
    NUTRIENTS, 2022, 14 (17)
  • [45] A Review of Defatting Strategies for Non-Alcoholic Fatty Liver Disease
    Young, Erin Nicole
    Doga, Murat
    Watkins, Christine
    Bajwa, Amandeep
    Eason, James D.
    Kuscu, Canan
    Kuscu, Cem
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (19)
  • [46] Non-alcoholic fatty liver disease and hematologic manifestations (Review)
    Padureanu, Vlad
    Dop, Dalia
    Dragoescu, Alice Nicoleta
    Padureanu, Rodica
    Musetescu, Anca Emanuela
    Nedelcu, Laurentiu
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2021, 22 (06)
  • [47] Levothyroxine and Non-alcoholic Fatty Liver Disease: A Mini Review
    Singha, Partha Sarathi
    Ghosh, Suvendu
    Ghosh, Debosree
    MINI-REVIEWS IN MEDICINAL CHEMISTRY, 2024, 24 (02) : 128 - 138
  • [48] Statins for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis
    Eslami, Layli
    Merat, Shahin
    Malekzadeh, Reza
    Nasseri-Moghaddam, Siavosh
    Aramin, Hermineh
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2013, (12):
  • [49] Non-alcoholic fatty liver disease, non-alcoholic steatohepatitis and orthotopic liver transplantation
    Burke, A
    Lucey, MR
    AMERICAN JOURNAL OF TRANSPLANTATION, 2004, 4 (05) : 686 - 693
  • [50] NON-ALCOHOLIC FATTY LIVER DISEASE AND NON-ALCOHOLIC FATTY PANCREAS DISEASE: A NEW INTRIGUING ASSOCIATION?
    Della Corte, Claudia
    Mosca, Antonella
    Sartorelli, Maria Rita
    Comparcola, Donatella
    Liccardo, Daniela
    Alterio, Arianna
    Lucidi, Vincenzina
    Nobili, Valerio
    DIGESTIVE AND LIVER DISEASE, 2014, 46 : E101 - E101
12345